Methicillin-resistant Staphylococcus aureus ST30-SCCmec IVc clone as the major cause of community-acquired invasive infections in Argentina

Infecciones por Staphylococcus aureus meticilino resistente adquirido en la comunidad: hospitalización y riesgo de letalidad en 10 centros pediátricos de Argentina

“…Asimismo, los factores de riesgo asociados a letalidad, como la edad ≥ 8 años, las formas clínicas de sepsis/bacteriemia, meningitis y neumonía, fueron similares a lo informado por otros estudios. 4,[33][34][35] Cabe destacar que la presencia de factores predisponentes, el sexo y las infecciones graves de tejidos blandos (fascitis y miositis) no se asociaron a mayor letalidad.…”

Community-acquired Staphylococcus aureus, a recent problem

“…Colonization may last weeks or months. 2,3 At present, it is a major health problem, at both the hospital and the community levels. It is very common to find SA in intensive care, neonatology, and surgery units.…”

“…Cases may be isolated or occur as part of an outbreak, and affect children of any age. During adolescence, SA is the most common causative agent of communityacquired sepsis, [3][4][5] probably due to transmission in dressing rooms used in relation to sport activities.…”

“…In addition, most strains contain the PantonValentine leukocidin (PVL), a toxin that causes neutrophil lysis and induces chemotactic factor release, which promote tissue inflammation and destruction, thus resulting in necrotizing pneumonia. 3,7,8 The recent emergence of vancomycinintermediate SA strains (VISA MICs of 4-8 µg/ mL and hetero-VISA) and even resistant strains (MICs > 16 µg/mL) have forced to look for alternative antibiotic approaches. There are currently multiple options, including daptomycin, linezolid, and ceftaroline.…”

“…Oral clindamycin, co-trimoxazole, or doxycycline may be used for mild infections without systemic complications, whereas serious infections require an empiric treatment with glycopeptides, linezolid, daptomycin, and tigecycline. 3,9 C o m b i n e d e m p i r i c t r e a t m e n t m a y b e useful in certain clinical settings, including critically-ill patients with a suspected antibioticresistant infection, given that it provides a broadened coverage and accounts for an adequate initial therapy.…”